Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.69M | 5.74M | 25.42M | 61.52M | 79.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.69M | 5.74M | 25.42M | 61.52M | 79.48M |
| Cost of Revenue | 139.04M | 141.55M | 140.57M | 141.72M | 134.61M |
| Gross Profit | -134.36M | -135.81M | -115.15M | -80.20M | -55.14M |
| SG&A Expenses | 40.27M | 40.70M | 40.85M | 41.36M | 41.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.31M | 182.25M | 181.42M | 183.08M | 175.64M |
| Operating Income | -174.63M | -176.51M | -156.00M | -121.56M | -96.16M |
| Income Before Tax | -164.96M | -165.16M | -142.83M | -104.49M | -76.91M |
| Income Tax Expenses | 819.00K | 962.00K | 924.00K | -1.04M | -3.55M |
| Earnings from Continuing Operations | -165.78 | -166.12 | -143.75 | -103.46 | -73.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.78M | -166.12M | -143.75M | -103.46M | -73.35M |
| EBIT | -174.63M | -176.51M | -156.00M | -121.56M | -96.16M |
| EBITDA | -170.86M | -172.56M | -151.90M | -117.36M | -92.26M |
| EPS Basic | -3.97 | -4.00 | -3.47 | -2.50 | -1.78 |
| Normalized Basic EPS | -2.44 | -2.46 | -2.13 | -1.58 | -1.17 |
| EPS Diluted | -3.97 | -4.00 | -3.47 | -2.51 | -1.79 |
| Normalized Diluted EPS | -2.44 | -2.46 | -2.13 | -1.58 | -1.17 |
| Average Basic Shares Outstanding | 167.12M | 166.24M | 165.48M | 164.72M | 163.88M |
| Average Diluted Shares Outstanding | 167.12M | 166.24M | 165.48M | 166.93M | 166.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |